Nanoencapsulated Curcumin: Enhanced Efficacy in Reversing Memory Loss in An Alzheimer Disease Model

Investigating new drugs or formulations that target Alzheimer disease (AD) is critical for advancing therapeutic interventions. Therefore, this study aimed to assess the effectiveness of nanoencapsulated curcumin (NC Curc) in alleviating memory impairment, oxidative stress, and neuroinflammation in...

Full description

Saved in:
Bibliographic Details
Published in:Brain sciences 2024-02, Vol.14 (2), p.130
Main Authors: Savall, Anne Suély Pinto, de Mello, Jhuly Dorneles, Fidelis, Eduarda Monteiro, Comis-Neto, Antonio Alvenir, Nepomuceno, Maria Regina, Pacheco, Camila de Oliveira, Haas, Sandra Elisa, Pinton, Simone
Format: Article
Language:English
Subjects:
Acetylcholinesterase
Advertising executives
Alzheimer's disease
Animal cognition
Animal models
Curcumin
Drug therapy
Glial fibrillary acidic protein
Health aspects
Inflammation
Memory
nanotechnology
Neurodegenerative diseases
neuroinflammation
Oxidative stress
Pattern recognition
Permeability
Streptozocin
streptozotocin
Target marketing
Therapeutic applications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Investigating new drugs or formulations that target Alzheimer disease (AD) is critical for advancing therapeutic interventions. Therefore, this study aimed to assess the effectiveness of nanoencapsulated curcumin (NC Curc) in alleviating memory impairment, oxidative stress, and neuroinflammation in a validated AD model. Male Wistar rats were given bilateral intracerebroventricular injections of either saline or streptozotocin (STZ) (3 mg/3 µL/site) to establish the AD model (day 0). On day 22, daily oral administrations of curcumin (6 mg/kg), NC Curc (6 mg/kg), or a vehicle (unloaded NC) were initiated and continued for 14 days. NC Curc significantly reversed memory deficits in object recognition and inhibitory avoidance tests induced by STZ. Both formulations of curcumin attenuated elevated acetylcholinesterase activity caused by STZ. Importantly, NC Curc alone effectively mitigated STZ-induced oxidative stress. Additionally, NC Curc treatment normalized GFAP levels, suggesting a potential reduction in neuroinflammation in STZ-treated rats. Our findings indicate that NC Curc improves memory in an AD rat model, highlighting its enhanced therapeutic effects compared to unencapsulated curcumin. This research significantly contributes to understanding the therapeutic and neurorestorative potential of NC Curc in AD, particularly in reversing pathophysiological changes.
ISSN:2076-3425
2076-3425
DOI:10.3390/brainsci14020130